Drug Channels

JANUARY 12, 2021

Once again, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have increased the number of drugs they have excluded from their standard formularies. . I also highlight the expansion of exclusions into major specialty therapy classes.

Pharmacy 52

Pharmacy Drugs Therapies Production 52

Drug Channels

NOVEMBER 8, 2020

You can download the complete agenda here. Visit www.informaconnect.com/trade-channel for further details and to register. Drug Channels readers will save $200 off the standard rate when they use code KTP933 and register prior to November 20th.*. Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Drug Channels

MARCH 22, 2021

Once again, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have increased the number of drugs they have excluded from their standard formularies. . I also highlight the expansion of exclusions into major specialty therapy classes.

Pharmacy 52

Pharmacy Drugs Therapies Production 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Abarca , a pharmacy benefit manager (PBM) that is disrupting the industry with a new approach to technology and business practices released a new case study detailing a value-based agreement with Biogen Inc. It started by redefining pharmacy benefits, but this is just the beginning. organization.

Production 40

Production Pharmacy Pharmaceutical Companies Therapies 40

The Pharma Data

JANUARY 13, 2021

At Usona, Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA. View original content to download multimedia: [link]. MindMed Co-CEO J.R.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 17, 2021

If the new therapy’s efficacy is confirmed, it could be administered to people who test positive for the virus through PCR and antigen tests in hospitals and primary care offices.” View original content to download multimedia: [link]. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Virus 52

The Pharma Data

NOVEMBER 18, 2020

It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health’s multispecialty physicians group.

Hospitals 40

Hospitals Treatment Virus Science 40